ReviewBreast cancer (Dove Medical Press)2013
Contribution of toll-like receptor signaling pathways to breast tumorigenesis and treatment.
Review in Breast cancer (Dove Medical Press), 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 25 citations in OpenAlex.
- Article
- Assessment of Cytotoxicity, Impact on Cell Migration and Apoptotic Modulation of Acteoside and Plantamajoside on Human Breast Adenocarcinoma (MCF-7).Asian Pacific journal of cancer prevention : APJCP · 2025Article
- Review
- Necroptosis-related LncRNAs in skin cutaneous melanoma: evaluating prognosis, predicting immunity, and guiding therapy.BMC cancer · 2023Article
- Therapeutic Nanocarriers Inhibit Chemotherapy-Induced Breast Cancer Metastasis.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2022Article
- The types of tumor infiltrating lymphocytes are valuable for the diagnosis and prognosis of breast cancer.Frontiers in genetics · 2022Article
- Expression profile of Toll‑like receptors in human breast cancer.Molecular medicine reports · 2020Article
- Unsupervised discovery of phenotype-specific multi-omics networks.Bioinformatics (Oxford, England) · 2019Article
- Protective Innate Immune Variants in Racial/Ethnic Disparities of Breast and Prostate Cancer.Cancer immunology research · 2019Review
- Testing for differentially expressed genetic pathways with single-subject N-of-1 data in the presence of inter-gene correlation.Statistical methods in medical research · 2018Article
- Osteopontin is involved in TLR4 pathway contributing to ovarian cancer cell proliferation and metastasis.Oncotarget · 2017Article
- Disease biomarker identification from gene network modules for metastasized breast cancer.Scientific reports · 2017Article
- Identification of novel biomarkers associated with poor patient outcomes in invasive breast carcinoma.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2016Article
- Proteoglycans: Potential Agents in Mammographic Density and the Associated Breast Cancer Risk.Journal of mammary gland biology and neoplasia · 2015Review
- Observational
- IRAK4 and TLR3 Sequence Variants may Alter Breast Cancer Risk among African-American Women.Frontiers in immunology · 2013Article
- Associations Between Serum Soluble Toll-like Receptors 4 and 9 and Breast Cancer in Egyptian Patients.Cancer control : journal of the Moffitt Cancer CenterArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
Abstract
Mounting evidence indicates that anomalies in the inflammatory and immune response pathways are essential to tumorigenesis. However, tumor-based innate immunity initiated by transformed breast epithelia tissues has received much less attention. This review summarizes published reports on the role of the toll-like receptor signaling pathway on breast cancer risk, disease progression, survival, and disease recurrence. Specifically, we discuss the underlying biological mechanisms that contribute to the tumorigenic and/or anti-tumorigenic properties of toll-like receptors and their associated agonists in relation to breast tumorigenesis and cancer treatment. Further, we use results from preclinical, clinical, and population-based studies as prompts for the exploration of new and more effective breast cancer therapies. As the knowledge base of innate immunity's involvement in breast cancer progression increases, current and new immune-modifying strategies will be refined to effectively treat breast cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.